Literature DB >> 15913839

Increase in tau tyrosine phosphorylation correlates with the formation of tau aggregates.

Irving E Vega1, Li Cui, Josh A Propst, Michael L Hutton, Gloria Lee, Shu-Hui Yen.   

Abstract

Tauopathies are neurodegenerative disorders characterized by aberrant intracellular aggregation of hyperphosphorylated tau. It has been shown that aggregated tau is phosphorylated at serine, threonine, and tyrosine residues. However, the occurrence of tyrosine phosphorylation on tau proteins at different states of tau aggregation has not been shown. In this report, we utilized the tauopathy mouse model JNPL3 that expresses human 0N4R tau isoform bearing the missense P301L mutation to study the occurrence of tau tyrosine phosphorylation in the course of the development of tau aggregation. These mice develop behavioral and motor deficits and form sarkosyl-insoluble hyperphosphorylated tau in an age-dependent manner. Mass spectrometry analyses of immunopurified brain tau proteins from JNPL3 and Alzheimer's disease affected individual uncovered novel tau tyrosine-phosphorylated sites. Further studies demonstrated that the abundance of tyrosine-phosphorylated tau increases in an age-dependent manner in JNPL3 mice. Tyrosine-phosphorylated tau was detected in both soluble and sarkosyl-insoluble preparations derived from brain and spinal cord, and localized in neurons containing aggregated tau. The phosphorylation of tyrosine residues in tau appeared to occur along with that of serine and threonine residues and was not detectable in non-transgenic littermates and transgenic mice expressing 0N4R wild-type human tau. The results suggest that tyrosine phosphorylation is as important as phosphorylation of other residues in tauopathy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15913839      PMCID: PMC3677942          DOI: 10.1016/j.molbrainres.2005.04.015

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  19 in total

1.  An immunochemical study on tau glycation in paired helical filaments.

Authors:  L W Ko; E C Ko; P Nacharaju; W K Liu; E Chang; A Kenessey; S H Yen
Journal:  Brain Res       Date:  1999-06-05       Impact factor: 3.252

Review 2.  Neurodegenerative tauopathies.

Authors:  V M Lee; M Goedert; J Q Trojanowski
Journal:  Annu Rev Neurosci       Date:  2001       Impact factor: 12.449

3.  Probability-based validation of protein identifications using a modified SEQUEST algorithm.

Authors:  Michael J MacCoss; Christine C Wu; John R Yates
Journal:  Anal Chem       Date:  2002-11-01       Impact factor: 6.986

4.  Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein.

Authors:  J Lewis; E McGowan; J Rockwood; H Melrose; P Nacharaju; M Van Slegtenhorst; K Gwinn-Hardy; M Paul Murphy; M Baker; X Yu; K Duff; J Hardy; A Corral; W L Lin; S H Yen; D W Dickson; P Davies; M Hutton
Journal:  Nat Genet       Date:  2000-08       Impact factor: 38.330

Review 5.  The characterization of protein post-translational modifications by mass spectrometry.

Authors:  Rebecca E Schweppe; Claire E Haydon; Timothy S Lewis; Katheryn A Resing; Natalie G Ahn
Journal:  Acc Chem Res       Date:  2003-06       Impact factor: 22.384

6.  Rapid tyrosine phosphorylation of neuronal proteins including tau and focal adhesion kinase in response to amyloid-beta peptide exposure: involvement of Src family protein kinases.

Authors:  Ritchie Williamson; Timothy Scales; Bruce R Clark; Graham Gibb; C Hugh Reynolds; Stuart Kellie; Ian N Bird; Ian M Varndell; Paul W Sheppard; Ian Everall; Brian H Anderton
Journal:  J Neurosci       Date:  2002-01-01       Impact factor: 6.167

7.  Tau assembly in inducible transfectants expressing wild-type or FTDP-17 tau.

Authors:  Michael DeTure; Li-Wen Ko; Colin Easson; Shu-Hui Yen
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

8.  Assembly of tau in transgenic animals expressing P301L tau: alteration of phosphorylation and solubility.

Authors:  Naruhiko Sahara; Jada Lewis; Michael DeTure; Eileen McGowan; Dennis W Dickson; Mike Hutton; Shu-Hui Yen
Journal:  J Neurochem       Date:  2002-12       Impact factor: 5.372

9.  Role of glycosylation in hyperphosphorylation of tau in Alzheimer's disease.

Authors:  Fei Liu; Tanweer Zaidi; Khalid Iqbal; Inge Grundke-Iqbal; Roberta K Merkle; Cheng Xin Gong
Journal:  FEBS Lett       Date:  2002-02-13       Impact factor: 4.124

10.  The permissive effect of zinc deficiency on uroguanylin and inducible nitric oxide synthase gene upregulation in rat intestine induced by interleukin 1alpha is rapidly reversed by zinc repletion.

Authors:  Li Cui; Raymond K Blanchard; Robert J Cousins
Journal:  J Nutr       Date:  2003-01       Impact factor: 4.798

View more
  34 in total

1.  Tau phosphorylated at tyrosine 394 is found in Alzheimer's disease tangles and can be a product of the Abl-related kinase, Arg.

Authors:  Matthew A Tremblay; Christopher M Acker; Peter Davies
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

Review 2.  Cellular factors modulating the mechanism of tau protein aggregation.

Authors:  Sarah N Fontaine; Jonathan J Sabbagh; Jeremy Baker; Carlos R Martinez-Licha; April Darling; Chad A Dickey
Journal:  Cell Mol Life Sci       Date:  2015-02-11       Impact factor: 9.261

3.  A novel calcium-binding protein is associated with tau proteins in tauopathy.

Authors:  Irving E Vega; Edwin E Traverso; Yancy Ferrer-Acosta; Eduardo Matos; Migdalisel Colon; John Gonzalez; Dennis Dickson; Michael Hutton; Jada Lewis; Shu H Yen
Journal:  J Neurochem       Date:  2008-07-01       Impact factor: 5.372

4.  Novel screening cascade identifies MKK4 as key kinase regulating Tau phosphorylation at Ser422.

Authors:  Fiona Grueninger; Bernd Bohrmann; Klaus Christensen; Martin Graf; Doris Roth; Christian Czech
Journal:  Mol Cell Biochem       Date:  2011-06-03       Impact factor: 3.396

Review 5.  c-Abl in neurodegenerative disease.

Authors:  Sarah D Schlatterer; Christopher M Acker; Peter Davies
Journal:  J Mol Neurosci       Date:  2011-07-05       Impact factor: 3.444

6.  Accelerated neurodegeneration and neuroinflammation in transgenic mice expressing P301L tau mutant and tau-tubulin kinase 1.

Authors:  Hirohide Asai; Seiko Ikezu; Maya E Woodbury; Grant M S Yonemoto; Libin Cui; Tsuneya Ikezu
Journal:  Am J Pathol       Date:  2014-01-10       Impact factor: 4.307

7.  Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease.

Authors:  Sudad Saman; WonHee Kim; Mario Raya; Yvonne Visnick; Suhad Miro; Sarmad Saman; Bruce Jackson; Ann C McKee; Victor E Alvarez; Norman C Y Lee; Garth F Hall
Journal:  J Biol Chem       Date:  2011-11-04       Impact factor: 5.157

8.  Role of PrP(C) Expression in Tau Protein Levels and Phosphorylation in Alzheimer's Disease Evolution.

Authors:  C Vergara; L Ordóñez-Gutiérrez; F Wandosell; I Ferrer; J A del Río; R Gavín
Journal:  Mol Neurobiol       Date:  2014-06-26       Impact factor: 5.590

9.  Vanadium induces dopaminergic neurotoxicity via protein kinase Cdelta dependent oxidative signaling mechanisms: relevance to etiopathogenesis of Parkinson's disease.

Authors:  Hilary Afeseh Ngwa; Arthi Kanthasamy; Vellareddy Anantharam; Chunjuan Song; Travis Witte; Robert Houk; Anumantha G Kanthasamy
Journal:  Toxicol Appl Pharmacol       Date:  2009-07-29       Impact factor: 4.219

Review 10.  Tau in physiology and pathology.

Authors:  Yipeng Wang; Eckhard Mandelkow
Journal:  Nat Rev Neurosci       Date:  2015-12-03       Impact factor: 34.870

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.